Pathos AI, a privately held AI-native oncology company, has entered a collaboration and co-exclusive licensing agreement with AstraZeneca (LSE/Nasdaq: AZN) to advance AZD4241, a preclinical oral estrogen receptor (ER) alfa proteolysis-targeting chimera (PROTAC), into early clinical development for estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. Pathos assumes responsibility for early clinical execution, applying its Foundry artificial intelligence platform to patient stratification and trial design.
AZD4241 is designed to degrade the estrogen receptor alpha protein, targeting both wild-type and mutated forms of the receptor. ESR1 mutations are present in up to 30–40% of patients whose disease progresses on standard endocrine therapy, according to the companies. PROTACs recruit the cell's ubiquitin-proteasome system to degrade the target protein rather than reversibly occupying its binding site.
The agreement arrives months after the FDA approved vepdegestrant (Veppanu), the first ERα PROTAC approved for ESR1-mutant ER+/HER2− advanced breast cancer, providing the first clinical validation of the therapeutic approach. Arvinas (Nasdaq: ARVN) and Pfizer originally collaborated on vepdegestrant in 2021 at a USD 650 million upfront, with Arvinas and Pfizer subsequently out-licensing Veppanu to Rigel Pharmaceuticals (Nasdaq: RIGL) for USD 70 million upfront plus up to USD 320 million in milestones. AZD4241 enters a post-approval competitive environment where differentiation will depend on demonstrating activity in broader ESR1 wild-type populations, earlier lines of therapy, or combination regimens not yet established for Veppanu.
The deal is the second partnership between Pathos and AstraZeneca. The two companies previously partnered with Tempus AI (Nasdaq: TEM), on a multi-year collaboration to build a multimodal oncology foundation model.